ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference

 

 

Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new  data will be presented  on the efficacy and mechanism of action of  imipridones ONC201 and ONC206 at the 24th Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona.

These data will highlight exciting findings that have emerged over the past year, including:

·       Updated clinical results for ONC201 in pediatric and adult H3 K27M-mutant gliomas

·       Extension of ONC201 activity to other brain tumors

·       Synergy antitumor activity of ONC201 in combination with other treatments

·       Activity of ONC206 in medulloblastoma

·       IND-enabling studies with ONC206

·       Distinctions in the activity of ONC201 and ONC206

·       Inhibition of mitochondrial function by ONC201

·       The capability of the imipridone family to bind to distinct molecular targets

Oncoceutics and academic investigators will present a range of results with imipridones that will include mechanistic and efficacy findings from preclinical models that detail their unique therapeutic potential in neuro-oncology. In addition, updated safety, pharmacokinetic, pharmacodynamic, and efficacy results from clinical trials with ONC201 in high-grade glioma patients will be reported. These results are largely derived from the ongoing clinical program that is dedicated to exploring ONC201 a molecularly-defined patient population (H3 K27M-mutant glioma). The rationale for the upcoming first-in-human clinical trial of ONC206 in adult recurrent CNS tumors will also be highlighted.

Summaries and presentation information are provided below:

Date/Time

Location

Abstract Title

Presenter

Wednesday

11/20

 

 

 

9:40 – 9:50 PM

JW Marriott

Selective targeting of dopamine receptor

dysregulation in high grade gliomas with ONC201

Varun Prabhu, PhD,

Oncoceutics

Thursday    

11/21

 

 

 

 

5:00 – 7:00 PM

 

 

Investigator Meeting

 

Friday

11/22

 

 

 

 

7:30 – 9:30 PM

Ballroom Lawn

Imipridone Structure Activity Relationship Uncovers ONC206 as the Next Bitopic DRD2 Antagonist for

                                                       Oncology with Differentiated Receptor Pharmacology                                                      

Varun Prabhu, PhD, Oncoceutics

 

7:30 - 9:30 PM

Ballroom Lawn

Single agent ONC201 in previously treated, progressive adult H3 K27M-mutant glioma

Isabel Arrillaga- Romany, MD, PhD,

                                                                                                                                             MGH                                                                                                                                            

7:30 - 9:30 PM

Ballroom

Lawn

Role of ONC206 in regulating medulloblastoma tumor

progression

Anshu Malhotra, PhD,

Emory University

7:38 - 7:42 PM

Wildflower B

Receptor pharmacology of ONC201: The first bitopic

DRD2 antagonist for clinical neuro-oncology

Josh Allen, PhD,

Oncoceutics

 

Saturday

11/23

 

 

 

 

7:15 - 8:30 AM

Grand Canyon 8-13

H3K27M glioma and ONC201 (SNO-EANO Joint session)

Isabel Arrillaga- Romany, MD, PhD,

                                                                                                                                             MGH                                                                                                                                            

3:45 - 3:55 PM

Grand Canyon

1-6

Clinical efficacy of ONC201 in thalamic H3 K27M-

mutant glioma

Carl Koschmann, MD,

Michigan Medicine

4:40 - 4:45 PM

Grand Canyon

1-6

Phase I clinical trial of ONC201 in pediatric H3 K27M-

mutant glioma or newly diagnosed DIPG

Sharon Gardner, MD,

NYU Langone Health

 

5:00 – 7:00 PM

 

Ballroom Lawn

Preclinical combination of ONC201 with radiotherapy or Temozolomide in GBM, DIPG and ATRT cell lines results in dopamine receptor antagonism, ATF4

                                                       induction and cell death                                                      

Lanlan Zhou, MD, PhD, Brown University

5:00 – 7:00 PM

Ballroom

Lawn

Metabolic rewiring by ONC201/TIC10 and 2-

Deoxyglucose has synergistic anti-glioblastoma activity

Josh Allen, PhD,

Oncoceutics

5:00 – 7:00 PM

Ballroom

Lawn

PDTM-25 Study of ONC201 in pre-clinical models of

DIPG

Wafik Zaky, MD, MD

Anderson

5:00 – 7:00 PM

Ballroom

Lawn

IND-enabling Characterization of ONC206 as the Next

Bitopic DRD2 antagonist for Neuro-oncology

Varun Prabhu, PhD,

Oncoceutics

  About Oncoceutics

Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, called “imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist, the first one that exhibits a highly specific bi-topic binding to the receptor. The company is supported by grants from the NCI, FDA, The Musella Foundation, and a series of private and public partnerships.

 

   Visit Oncoceutics  for more information.

 

ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference

ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference

alexvarney

2 weeks
8 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
2 Views
Cancer-News 1 day
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
26 Views
Cancer-News 2 days
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 2 days
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
10 Views
kidneycancer 2 days
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 2 days
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
4 Views
kidneycancer 3 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
5 Views
Cancer-News 3 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 3 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
10 Views
kidneycancer 3 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
3 Views
Cancer-News 4 days